AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01398891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Psychology Exercises
Description: At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
Study NCT01100411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua
Description: Contact lens material: Lotrafilcon A
Study NCT01100411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofinity
Description: Contact lens material: Comfilcon A
Study NCT01100411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proclear
Description: Contact lens material: Omafilcon A
Study NCT01100411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys
Description: Contact lens material: Senofilcon A
Study NCT01100411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue 2
Description: Contact lens material: Etafilcon A
Study NCT01100411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Purevision
Description: Contact lens material: Balafilcon A
Study NCT00972803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pistacia Mutica extract
Description: The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
Study NCT00972803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects were asked to use a placebo mouthwash twice a day for 4 days.
Study NCT00972803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
Study NCT00911261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone Extended Release
Description: * Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~* Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~* Treatment will consist of up to 12 months of dosing with Oxymorphone ER.
Study NCT02600637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness-based Stress Reduction is an 8-week course designed to teach a number of mindfulness techniques to help improve stress- and depression-related symptoms.
Study NCT02600637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health class
Description: An 8-week course on brain health will be administered to participants as an active control group.
Study NCT03345927 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00133276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
Study NCT00133276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04393961 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette
Description: Current emergency situation, there are large numbers of COVID-19 Antibody tests being made available at a record pace.~The protocol is designed to be test agnostic. However, for this first volley, we have chosen the The COVID-19 IgG and IgM Rapid Test provided by Premier Biotech.~We chose the Precision Bio test for 4 reasons~1. It is available as a single use test kit in one sealed unit.~2. It's a rapid test, with results available in 10 minutes.~3. It has clear and easy to read instructions already included~4. It has one of the lowest false positive rates of known tests at the moment
Study NCT02120976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-252 or Placebo
Description: Subjects will receive JTT-252 or Placebo
Study NCT02120976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-252
Description: Subjects will receive JTT-252
Study NCT04488120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcatheter closure of secundum atrial septal defects in patients
Description: transcatheter closure of secundum atrial septal defects in patients
Study NCT04488120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcatheter closure of secundum atrial septal defects in patients
Description: transcatheter closure of secundum atrial septal defects in patients
Study NCT03010878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.~Yoga was delivered in sitting, standing, and floor postures
Study NCT03010878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management
Description: The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
Study NCT03864237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol texts
Description: A text message each day for 10 weeks, containing factual information about campus drinking norms.
Study NCT03864237 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: A text message each day for 10 weeks, containing this day in history facts.
Study NCT04848740 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ReLex-smile
Description: Using VisuMax femtosecond laser we created the stromal pocket with diameter of 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness set to 130 μm from corneal surface and 4 mm superior incision. Hinge position flap was set at 90° angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values We noticed during intervention that implantation of fresh lenticule depends from corneal thickness, for example if c.th.is 300-400 μm we implanted 1/2 stroma, if c.th.is 400 μm or more we implanted 1/3 stroma Example: if corneal thickness is 300 μm we implanted 150 μm (becoming 450 μm) we added more stroma due to more live keratocytes and stromal steam cells, aiming to overcome dead and non-functional keratocytes
Study NCT02364856 — intervention group
Intervention type: DEVICE
Intervention: Analgesia Nociception Index
Description: The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.~ANI is calculated from heart rate recording.
Study NCT01474356 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: hyperthermia
Description: 45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
Study NCT02982122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
Description: For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
Study NCT02982122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
Description: For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
Study NCT01474356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperthermia
Description: 45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
Study NCT03924362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCNL
Description: Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.
Study NCT01351961 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Urine sample
Study NCT01858766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily
Study NCT01736488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: Fimasartan 60mg
Study NCT03777293 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ultrasound viscoelasticity
Description: use these devices to do ultrasound examination in chronic liver disease patients
Study NCT04259749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavor Ban
Description: Only flavored tobacco products are banned
Study NCT03777293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound viscoelasticity
Description: use these devices to do ultrasound examination in chronic liver disease patients
Study NCT03553732 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: Patients who are diagnosed with prostate cancer and elect to be monitored by an Active Surveillance protocol by the Urology Clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing but suboptimal systems for tracking patients. All Active Surveillance patients monitored by the clinic will be included.
Study NCT01611181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemoboost
Description: 200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
Study NCT01611181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kräuterblut
Description: 40 mg iron, 20 ml twice daily.
Study NCT01611181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrofumerat
Description: 200 mg ferrous sulphate as 1 tablet twice daily.
Study NCT02858245 — intervention group
Intervention type: OTHER
Intervention: No intervention - registry
Study NCT03843879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Description: Single-injection transversus abdominis plane block with 30 mL of 0.25% Bupivacaine with 1:400,000 epinephrine
Study NCT03843879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Lidocaine
Description: Continuous intravenous lidocaine infusion
Study NCT02643654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MABp1
Description: This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
Study NCT02643654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
Study NCT00504686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy
Description: manual therapy - thoracic spine thrust manipulation
Study NCT00504686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: therapeutic exercise
Study NCT04259749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Ban
Description: Mentholated products are banned
Study NCT04259749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All flavored and mentholated products available
Description: No bans: All tobacco products are available
Study NCT01579240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet exercise program
Description: 12 voluntary weekly visits to website
Study NCT04201652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial local anesthetic infiltration
Description: Superficial infiltration of local anesthetic for carpal tunnel release.
Study NCT04201652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep local anesthetic infiltration
Description: Deep and superficial infiltration of local anesthetic for carpal tunnel release.
Study NCT02895386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROX Coupler
Description: ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
Study NCT02895386 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure + continuing current antihypertensive medications.
Study NCT03861260 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rigid cystoscopy with urethral dilatation
Description: Patients will have a general anaesthetic and a rigid cytoscopic examination of the bladder dilated with sterile water. The urethra will be dilated from FR20 in incremental diameter increases of 2 to French 32 if possible.
Study NCT03861260 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flexible cystoscopy and installation of Glycosaminoglycan layer replacement (laluril)
Description: Patients will undergo flexible cystoscopy and intravesical installations of Hyaluronic acid (HA) + Chondroitin Sulphate (CS) (GAGs) weekly for 4 weeks and then at 8 weeks and 12 weeks.
Study NCT02038595 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging
Study NCT02883296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvis Magnetic resonance imaging
Study NCT02651740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 400mg tid\* 3d
Study NCT02651740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
Study NCT04411316 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Catheter directed thrombolysis plus anticoagulation
Description: Patients will be randomized to pharmacomechanical catheter directed thrombolysis plus anticoagulation.~PCDT will be AngioJet along with alteplase.
Study NCT04411316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation
Description: Patients will receive anticoagulation alone. Anticoagulation will be heparin only.
Study NCT01489449 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stent
Description: bare metal stent implantation, any bare metal stent is allowed from different companies
Study NCT01489449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent(R) Please coated balloon
Description: Angioplasty with Drug coated balloon (DCB)
Study NCT01475539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio
Description: 0.5 mL, Intramuscular + 1g dragee candy oral dose
Study NCT01858766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEL
Description: Tablet administered orally once daily
Study NCT01858766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01475539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live oral poliovirus type 1, 2 and 3
Description: 1g dragee candy, oral
Study NCT01736488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Atenolol 50mg
Study NCT02841020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional biopsy
Description: • Patients in the experimental group receive the additional biopsy for non-neoplastic disease during the same procedure before the biopsy of the renal mass (with potential for direct benefit to the patient by revealing non-neoplastic renal disease).
Study NCT04180696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aCRT ON
Description: CRT device with AdaptivCRT enabled
Study NCT01625559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: MA09-hRPE cells
Study NCT00354120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alentuzumab
Description: Alentuzumab
Study NCT04180696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aCRT OFF
Description: CRT device with AdaptivCRT disabled
Study NCT00842348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: Autogel 120 mg
Study NCT03942978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Longitudinal Equity Action Plan
Description: Patients admitted to general medicine pod randomized to intervention will receive a Longitudinal Equity Action Plan (LEAP), which will include a program manager to ensure they are on appropriate medical therapy, that cardiology is consulted when appropriate, that patient is set up with appropriate follow-up appointment with cardiology, that transportation is set up for follow-up visits, and a post-discharge follow up call to remind patients of the appointment and identify any post-discharge issues. This is in addition to standard of care, and there will not be any drug or device interventions.
Study NCT00354120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Globulina antilinfocitaria
Description: Globulina antilinfocitaria
Study NCT03029052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reconciliation
Description: In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
Study NCT02607904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study NCT03326323 — intervention group
Intervention type: PROCEDURE
Intervention: Acute Normovolemic Hemodilution
Description: Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
Study NCT03081494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spartalizumab (PDR001)
Description: 100 mg lyophilisate in vial received 400 mg every 4 weeks
Study NCT03081494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: 120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
Study NCT00779506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate XR
Description: oral, once daily, flexible dose
Study NCT03563807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Golf Instruction
Description: Subjects will participate in two weekly hour-long golf classes. Classes will be led by professional golf instructors that will work with individuals to teach participants how to play golf. This will include stretching, individual coaching, and working with participants to maximize their golf swing.
Study NCT03563807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi Class
Description: Tai Chi is an ancient martial art that uses meditative movement to improve strength, flexibility, and balance. Subjects will participate in two weekly hour-long Tai Chi classes.The class will be led by a certified Tai Chi instructor and consist of approximately 12 people.
Study NCT02944604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Study NCT02809872 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Thoracic Ultrasound
Study NCT02094001 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)
Description: After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
Study NCT04336891 — intervention group
Intervention type: DRUG
Intervention: Testosterone gel
Description: Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
Study NCT04336891 — intervention group
Intervention type: DRUG
Intervention: Estradiol ovules
Description: Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
Study NCT04336891 — intervention group
Intervention type: DRUG
Intervention: Moisturizer
Description: Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed